Literature DB >> 15247258

Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.

Kirk W Siddals1, Emma Marshman, Melissa Westwood, J Martin Gibson.   

Abstract

The vasculoprotective effects of hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins) correlate with cholesterol lowering. HMG-CoA reductase inhibitors also disrupt cellular processes by the depletion of isoprenoids and dolichol. Insulin and insulin-like growth factor (IGF) signaling appear particularly prone to such disruption as intracellular receptor processing requires dolichol for correct N-glycosylation, whereas downstream signaling through Ras requires the appropriate prenylation (farnesol). We determined how HMG-CoA reductase inhibition affected the mitogenic effects of IGF-I and metabolic actions of insulin in 3T3-L1 cells and examined the respective roles of receptor glycosylation and Ras prenylation. IGF-I- and insulin-induced proliferation was significantly reduced by all statins tested, although cerivastatin (10 nm) had the greatest effect (p < 0.005). Although inhibitors of Ras prenylation induced similar results (10 microm FTI-277 89% +/- 7.4%, p < 0.01), the effect of HMG-CoA reductase inhibition could only be partially reversed by farnesyl pyrophosphate refeeding. Treatment with statins resulted in decreased membrane expression of receptors and accumulation of proreceptors, suggesting disruption of glycosylation-dependent cleavage. Glycosylation inhibitors inhibited IGF-I-induced proliferation (tunicamycin p < 0.005, castanospermine p < 0.01, deoxymannojirimycin p < 0.01). High concentrations of statin were necessary to impair insulin-mediated glucose uptake (300 nm = 33% +/- 12% p < 0.05), and this process was not effected by farnesyl transferase inhibition. Gycosylation inhibitors mimicked the effect of statin treatment (tunicamycin p < 0.001, castanospermine p < 0.05, deoxymannojirimycin p < 0.05), and there was insulin proreceptor accumulation. These data imply that HMG-CoA reductase inhibitors disrupt IGF-I signaling by combined effects on Ras prenylation and IGF receptor glycosylation, whereas insulin signaling is only affected by disrupted receptor glycosylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247258     DOI: 10.1074/jbc.M404838200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

Review 2.  Modulation of h(2)s metabolism by statins: a new aspect of cardiovascular pharmacology.

Authors:  Jerzy Bełtowski; Anna Jamroz-Wiśniewska
Journal:  Antioxid Redox Signal       Date:  2011-12-19       Impact factor: 8.401

3.  Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization.

Authors:  Kirk W Siddals; Justine Allen; Smeeta Sinha; Ann E Canfield; Philip A Kalra; J Martin Gibson
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

4.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect.

Authors:  Peirang Cao; Jun-Ichi Hanai; Preeti Tanksale; Shintaro Imamura; Vikas P Sukhatme; Stewart H Lecker
Journal:  FASEB J       Date:  2009-04-30       Impact factor: 5.191

6.  In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent.

Authors:  Elena Maksimova; Ting-An Yie; William N Rom
Journal:  Lung       Date:  2007-11-22       Impact factor: 2.584

7.  Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.

Authors:  Allen B Williams; Li Li; Bao Nguyen; Patrick Brown; Mark Levis; Donald Small
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

8.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

Review 9.  HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Statins in the treatment of polycystic ovary syndrome.

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Semin Reprod Med       Date:  2008-01       Impact factor: 1.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.